BR112017005245A2 - animal não humano geneticamente modificado, métodos para produzir célula t, hibridoma de célula t, um ácido nucleico, um anticorpo específico, uma célula humana, um animal não humano geneticamente modificado e para induzir uma resposta imunológica, célula, hibridoma de célula t, ácido nucleico, anticorpo específico, receptor de antígeno quimérico, embrião não humano, locus de um receptor de antígeno quimérico, e, composição de ácidos nucleicos. - Google Patents

animal não humano geneticamente modificado, métodos para produzir célula t, hibridoma de célula t, um ácido nucleico, um anticorpo específico, uma célula humana, um animal não humano geneticamente modificado e para induzir uma resposta imunológica, célula, hibridoma de célula t, ácido nucleico, anticorpo específico, receptor de antígeno quimérico, embrião não humano, locus de um receptor de antígeno quimérico, e, composição de ácidos nucleicos.

Info

Publication number
BR112017005245A2
BR112017005245A2 BR112017005245A BR112017005245A BR112017005245A2 BR 112017005245 A2 BR112017005245 A2 BR 112017005245A2 BR 112017005245 A BR112017005245 A BR 112017005245A BR 112017005245 A BR112017005245 A BR 112017005245A BR 112017005245 A2 BR112017005245 A2 BR 112017005245A2
Authority
BR
Brazil
Prior art keywords
cell
nucleic acid
chimeric antigen
genetically modified
specific antibody
Prior art date
Application number
BR112017005245A
Other languages
English (en)
Inventor
J Murphy Andrew
Gurer Cagan
Thurston Gavin
Mcwhirter John
Macdonald Lynn
Tu Naxin
Voronina Vera
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112017005245A2 publication Critical patent/BR112017005245A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Husbandry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

são aqui fornecidos métodos e composições relacionados aos receptores de antígeno quiméricos (cars) tendo domínios de ligação ao antígeno derivados de uma imunoglobulina (qg) e domínios constantes derivados de um receptor de célula t (tcr).
BR112017005245A 2014-09-19 2015-09-18 animal não humano geneticamente modificado, métodos para produzir célula t, hibridoma de célula t, um ácido nucleico, um anticorpo específico, uma célula humana, um animal não humano geneticamente modificado e para induzir uma resposta imunológica, célula, hibridoma de célula t, ácido nucleico, anticorpo específico, receptor de antígeno quimérico, embrião não humano, locus de um receptor de antígeno quimérico, e, composição de ácidos nucleicos. BR112017005245A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462052947P 2014-09-19 2014-09-19
US201462052901P 2014-09-19 2014-09-19
US201462076836P 2014-11-07 2014-11-07
US201462094603P 2014-12-19 2014-12-19
US201562167650P 2015-05-28 2015-05-28
PCT/US2015/050975 WO2016044745A1 (en) 2014-09-19 2015-09-18 Chimeric antigen receptors

Publications (1)

Publication Number Publication Date
BR112017005245A2 true BR112017005245A2 (pt) 2017-12-12

Family

ID=54261082

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017005245A BR112017005245A2 (pt) 2014-09-19 2015-09-18 animal não humano geneticamente modificado, métodos para produzir célula t, hibridoma de célula t, um ácido nucleico, um anticorpo específico, uma célula humana, um animal não humano geneticamente modificado e para induzir uma resposta imunológica, célula, hibridoma de célula t, ácido nucleico, anticorpo específico, receptor de antígeno quimérico, embrião não humano, locus de um receptor de antígeno quimérico, e, composição de ácidos nucleicos.

Country Status (13)

Country Link
US (1) US20160081314A1 (pt)
EP (1) EP3193592A1 (pt)
JP (1) JP2017529841A (pt)
KR (1) KR20170083534A (pt)
CN (1) CN107072184A (pt)
AU (1) AU2015317370A1 (pt)
BR (1) BR112017005245A2 (pt)
CA (1) CA2959428A1 (pt)
IL (1) IL250536A0 (pt)
MX (1) MX2017003640A (pt)
RU (1) RU2017113134A (pt)
SG (1) SG11201701040XA (pt)
WO (1) WO2016044745A1 (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150064153A1 (en) 2013-03-15 2015-03-05 The Trustees Of Princeton University High efficiency microfluidic purification of stem cells to improve transplants
CN105264127B (zh) 2013-03-15 2019-04-09 Gpb科学有限责任公司 颗粒的片上微流体处理
CN113512522A (zh) 2013-03-15 2021-10-19 普林斯顿大学理事会 用于高通量纯化的方法和设备
CN106068276B (zh) * 2014-03-05 2020-09-18 Ucl商务有限公司 具有针对T细胞受体beta恒定区的抗原结合域的嵌合抗原受体(CAR)
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
US11885807B2 (en) 2014-03-05 2024-01-30 Autolus Limited Method for depleting malignant T-cells
FR3029449B1 (fr) * 2014-12-03 2017-10-13 Pole De Plasturgie De Lest Dispositif de moulage pour la fabrication de pieces en materiau composite a partir de resine polymere liquide.
RU2707137C2 (ru) * 2014-12-19 2019-11-22 Регенерон Фармасьютикалз, Инк. Способы и композиции для нацеленной генетической модификации посредством одноэтапного множественного нацеливания
KR102138209B1 (ko) 2015-05-06 2020-07-28 스니프르 테크놀로지스 리미티드 미생물 개체군 변경 및 미생물군 변형
US10976232B2 (en) 2015-08-24 2021-04-13 Gpb Scientific, Inc. Methods and devices for multi-step cell purification and concentration
DK3359660T3 (en) 2015-10-05 2020-02-17 Prec Biosciences Inc Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
EP3756682B8 (en) * 2015-10-05 2022-04-27 Precision Biosciences, Inc. Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene
CN109328074A (zh) 2016-04-01 2019-02-12 凯德药业股份有限公司 嵌合抗原和t细胞受体及使用的方法
CR20210084A (es) 2016-04-01 2021-03-26 Amgen Inc Receptores quiméricos y métodos de uso de los mismos (divisional 2018-0480)
CN117903307A (zh) 2016-04-01 2024-04-19 凯德药业股份有限公司 Bcma结合分子及其使用方法
BR112018071199A2 (pt) 2016-04-15 2019-02-12 Memorial Sloan Kettering Cancer Center célula t, população isolada de células t, composição farmacêutica, método de tratamento, método para gerar uma célula t, vetor, célula tronco
CN116458475A (zh) * 2016-06-03 2023-07-21 瑞泽恩制药公司 表达外源末端脱氧核苷酸转移酶的非人动物
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
EP3484284A1 (en) * 2016-07-12 2019-05-22 Kymab Limited Animals, cells, ligands, polypeptides & methods
SG10201913583QA (en) 2016-08-23 2020-02-27 Univ California Proteolytically cleavable chimeric polypeptides and methods of use thereof
WO2018075586A1 (en) * 2016-10-18 2018-04-26 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof
US11242402B2 (en) 2016-12-23 2022-02-08 Macrogenics, Inc. ADAM9-binding molecules, and methods of use thereof
US20190359678A1 (en) * 2017-02-09 2019-11-28 The Regents Of The University Of California Chimeric t cell antigen receptors and methods of use thereof
US20180280437A1 (en) 2017-03-13 2018-10-04 Kite Pharma, Inc. Chimeric antigen receptors for melanoma and uses thereof
WO2018184558A1 (zh) * 2017-04-05 2018-10-11 凯惠科技发展(上海)有限公司 一种人源化抗tpbg抗体及其制备方法、其偶联物和应用
JOP20180042A1 (ar) 2017-04-24 2019-01-30 Kite Pharma Inc نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
WO2019005957A1 (en) 2017-06-30 2019-01-03 Precision Biosciences, Inc. GENETICALLY MODIFIED T CELLS COMPRISING A MODIFIED INTRON IN THE ALPHA T CELL RECEPTOR GENE
SG11201912235PA (en) 2017-07-31 2020-01-30 Regeneron Pharma Cas-transgenic mouse embryonic stem cells and mice and uses thereof
MX2020001177A (es) 2017-07-31 2020-09-25 Regeneron Pharma Animales no humanos reporteros de crispr y usos de los mismos.
WO2019046052A1 (en) 2017-09-01 2019-03-07 Gpb Scientific, Llc METHODS FOR PREPARING THERAPEUTICALLY ACTIVE CELLS USING MICROFLUIDIC
AU2018337142A1 (en) 2017-09-22 2020-05-07 Wuxi Biologics Ireland Limited. Novel bispecific CD3/CD19 polypeptide complexes
MX2020003145A (es) 2017-09-22 2020-07-29 Wuxi Biologics Ireland Ltd Nuevos complejos de polipeptidos biespecificos.
MX2020003589A (es) 2017-09-29 2020-07-22 Regeneron Pharma Animales no humanos que comprenden un locus ttr humanizado y metodos de uso.
KR102503130B1 (ko) 2017-10-27 2023-02-24 더 리전트 오브 더 유니버시티 오브 캘리포니아 내인성 t 세포 수용체의 표적화된 대체
US11390655B2 (en) 2017-11-16 2022-07-19 Kite Pharma, Inc. Modified chimeric antigen receptors and methods of use
SG11202002456WA (en) * 2017-11-30 2020-04-29 Regeneron Pharma Non-human animals comprising a humanized trkb locus
CN112534044A (zh) 2018-02-16 2021-03-19 凯德药业股份有限公司 经修饰的多能干细胞及制备和使用方法
CA3089331A1 (en) 2018-03-19 2019-09-26 Regeneron Pharmaceuticals, Inc. Transcription modulation in animals using crispr/cas systems
CN112040769B (zh) * 2018-03-24 2023-05-16 瑞泽恩制药公司 用于产生针对肽-mhc复合物的治疗抗体的经过基因修饰的非人动物、制造方法和用途
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
CN108424931A (zh) * 2018-03-29 2018-08-21 内蒙古大学 CRISPR/Cas9技术介导山羊VEGF基因定点整合的方法
AU2019252527B2 (en) 2018-04-12 2024-02-22 Precision Biosciences, Inc. Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
EP3893899A2 (en) 2018-12-12 2021-10-20 Kite Pharma, Inc. Chimeric antigen receptors and car-t cells and methods of use
CN113272319A (zh) * 2018-12-27 2021-08-17 国立大学法人京都大学 T细胞受体的变体
CA3133360A1 (en) 2019-04-04 2020-10-08 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized coagulation factor 12 locus
US11891618B2 (en) 2019-06-04 2024-02-06 Regeneron Pharmaceuticals, Inc. Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use
AU2020289581A1 (en) 2019-06-07 2021-11-18 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized albumin locus
BR112021026831A2 (pt) * 2019-07-03 2022-02-22 Regeneron Pharma Proteínas de ligação ao antígeno anti-carcinoma de células escamosas esofágicas new york 1 (ny-eso-1) e métodos de uso das mesmas
US20220267726A1 (en) 2019-07-18 2022-08-25 Gpb Scientific, Inc. Ordered processing of blood products to produce therapeutically active cells
US20230028754A1 (en) 2019-12-28 2023-01-26 Gpb Scientific, Inc. Microfluidic cartridges for processing particles and cells
CN111320703A (zh) * 2020-03-11 2020-06-23 北京双赢科创生物科技有限公司 靶向cd22的嵌合抗原受体及其应用
WO2021190580A1 (en) * 2020-03-26 2021-09-30 Wuxi Biologics (Shanghai) Co., Ltd. Bispecific polypeptide complexes, compositions, and methods of preparation and use
EP4200023A1 (en) * 2020-08-23 2023-06-28 Applied StemCell, Inc. Hla-f-modified cells and methods
WO2022236049A1 (en) * 2021-05-07 2022-11-10 Senti Biosciences, Inc. Chimeric antigen receptors and methods of use
EP4215042A1 (en) * 2022-01-21 2023-07-26 Max-Delbrück-Centrum für Molekulare Medizin A non-human mammal comprising in its genome at least two human leukocyte antigen (hla) class i alleles, methods of making such mammal and uses thereof
CN116138212B (zh) * 2023-01-11 2024-03-05 江苏省中医院 一种制备细胞因子释放综合征小鼠模型的方法及应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
JPS6463394A (en) * 1987-09-04 1989-03-09 Kyowa Hakko Kogyo Kk Novel chimera polypeptide
IL86278A (en) * 1988-05-04 2003-06-24 Yeda Res & Dev Endowing cells with antibody specificity using chimeric t cell receptor
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6045796A (en) 1992-12-17 2000-04-04 Anergen, Inc. Vaccination with peptide of MHC class II molecules for treatment of autoimmune disease
US5512295A (en) 1994-11-10 1996-04-30 The Board Of Trustees Of The Leland Stanford Junior University Synthetic liposomes for enhanced uptake and delivery
US6001349A (en) 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869270A (en) 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
US6770291B2 (en) 1996-08-30 2004-08-03 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
US7001614B2 (en) 1996-08-19 2006-02-21 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US7112338B2 (en) 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US6749863B1 (en) 1997-11-19 2004-06-15 Georgetown University Targeted liposome gene delivery
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP1485075A4 (en) 2002-02-20 2006-04-26 Dyax Corp MHC-PEPTIDE COMPLEX BINDING LIGANDS
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US20090042291A1 (en) 2002-03-01 2009-02-12 Xencor, Inc. Optimized Fc variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040072262A1 (en) 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
US8663622B2 (en) 2002-12-16 2014-03-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant vaccine viruses expressing IL-15 and methods using the same
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
US8218805B2 (en) 2003-10-11 2012-07-10 Charles Hornback Wireless speaker system for use with ceiling fans
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
AU2005206536B2 (en) 2004-01-16 2010-09-02 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
US20060034850A1 (en) 2004-05-27 2006-02-16 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
PT1802193E (pt) 2004-10-19 2014-06-23 Regeneron Pharma Método para gerar um murganho homozigótico para uma modificação genética
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US20060222653A1 (en) 2004-11-12 2006-10-05 Xencor, Inc. Antibodies operably linked to selected chemoattractants
EP1858925A2 (en) 2005-01-12 2007-11-28 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
US20070190063A1 (en) 2005-08-19 2007-08-16 Bahjat Keith S Antibody-mediated enhancement of immune response
ES2735531T3 (es) 2005-08-23 2019-12-19 Univ Pennsylvania ARN que contiene nucleósidos modificados y métodos de uso del mismo
EP2003960B1 (en) 2006-03-31 2015-06-10 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
KR20160065985A (ko) 2007-10-18 2016-06-09 버베리안 노딕 에이/에스 전립선 암 치료를 위한 ｍｖａ의 용도
US8225343B2 (en) 2008-01-11 2012-07-17 Sony Computer Entertainment America Llc Gesture cataloging and recognition
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
US20120204278A1 (en) 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
PT2505654T (pt) 2010-02-08 2016-11-18 Regeneron Pharma Rato de cadeia leve comum
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
WO2011120134A1 (en) 2010-03-29 2011-10-06 Zymeworks, Inc. Antibodies with enhanced or suppressed effector function
PT2905338T (pt) 2010-06-22 2017-11-10 Regeneron Pharma Ratinhos transgénicos com um locus de imunoglobulina lambda endógeno modificado
US8539547B2 (en) 2010-08-18 2013-09-17 Certes Networks, Inc. Policy selector representation for fast retrieval
ES2748832T5 (es) 2011-02-25 2023-06-08 Regeneron Pharma Ratones ADAM6
JP5893258B2 (ja) 2011-03-31 2016-03-23 フェリカネットワークス株式会社 情報処理装置および方法、並びにプログラム
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
IL305550A (en) * 2011-10-28 2023-10-01 Regeneron Pharma Mice with a genetic change in the T cell receptor
US9591835B2 (en) 2011-10-28 2017-03-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
MY164836A (en) 2011-10-28 2018-01-30 Regeneron Pharma Genetically modified major histocompatibility complex mice
LT3590332T (lt) 2011-10-28 2022-08-10 Regeneron Pharmaceuticals, Inc. Genetiškai modifikuotos pelės, ekspresuojančios chimerines pagrindinio audinių dermės komplekso (mhc) ii molekules
CN104080811B (zh) 2011-11-04 2019-09-27 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
US9547499B2 (en) 2011-12-09 2017-01-17 Microsoft Technology Licensing, Llc Device configuration with cached pre-assembled driver state
WO2013126726A1 (en) * 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
JP5920830B2 (ja) 2012-09-28 2016-05-18 シスメックス株式会社 試料調製装置および細胞分析装置
AU2014218915B2 (en) 2013-02-20 2017-01-19 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
PL2958938T3 (pl) 2013-02-20 2019-11-29 Regeneron Pharma Myszy eksprymujące humanizowane ko-receptory komórek t
PL2958937T3 (pl) 2013-02-22 2019-01-31 Regeneron Pharmaceuticals, Inc. Myszy ekspresjonujące humanizowany główny układ zgodności tkankowej

Also Published As

Publication number Publication date
SG11201701040XA (en) 2017-03-30
MX2017003640A (es) 2017-10-31
IL250536A0 (en) 2017-03-30
AU2015317370A1 (en) 2017-03-23
RU2017113134A (ru) 2018-10-19
KR20170083534A (ko) 2017-07-18
US20160081314A1 (en) 2016-03-24
CA2959428A1 (en) 2016-03-24
EP3193592A1 (en) 2017-07-26
WO2016044745A1 (en) 2016-03-24
CN107072184A (zh) 2017-08-18
JP2017529841A (ja) 2017-10-12

Similar Documents

Publication Publication Date Title
BR112017005245A2 (pt) animal não humano geneticamente modificado, métodos para produzir célula t, hibridoma de célula t, um ácido nucleico, um anticorpo específico, uma célula humana, um animal não humano geneticamente modificado e para induzir uma resposta imunológica, célula, hibridoma de célula t, ácido nucleico, anticorpo específico, receptor de antígeno quimérico, embrião não humano, locus de um receptor de antígeno quimérico, e, composição de ácidos nucleicos.
CO2018001405A2 (es) Receptores de antígenos quiméricos basados en anticuerpos de dominio simple
IL279854A (en) A chimeric T-cell antigen receptor derived from immunoengineered pluripotent stem cells
CY1125008T1 (el) Χιμαιρικοι υποδοχεις αντιγονων που στοχευουν συζευγμενους με πρωτεϊνη g yποδοχεις και χρησεις αυτων
IL278878A (en) A chimeric antigen receptor having antigen-binding regions for the beta T-cell receptor constant region
BR112018067698A2 (pt) células modificadas para imunoterapia
BR112018010385A2 (pt) anticorpo, receptor de antígeno quimérico, ácido nucleico, célula recombinante, processo para produção de um anticorpo ou um receptor de antígeno quimérico, composição, e, método para detecção de uma célula que expressa cll-1, para diagnóstico de uma doença, para inibição de divisão da célula e para tratamento de um câncer.
CO2017006808A2 (es) Receptores de antígenos quiméricos de bcma
BR112017018770A2 (pt) redução da tolerância imunológica induzida por pd-l1
EP3440191A4 (en) CHIMERIC ANTIGEN RECEPTOR T CELL LYMPHOCYTE COMPOSITIONS
PT3443075T (pt) Células t transgénicas e composições de células t que expressam um recetor antigénico quimérico e métodos relacionados
EP3360961A4 (en) PROCESS FOR THE PREPARATION OF GENETICALLY MODIFIED T LYMPHOCYTES EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR
MX2022000132A (es) Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t.
MX2016012713A (es) Inmunoreceptores especificos de claudina-6 y epitopos de celulas t.
WO2014011993A3 (en) Epitope spreading associated with car t-cells
EP4303229A3 (en) Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
BR112015019350A2 (pt) Animal não humano, locus de imunoglobulina, e, métodos de fabricação de um animal não humano, para a obtenção de uma sequência de ácido nucleico e de fabricação de uma proteína de ligação ao antígeno
EA201590208A1 (ru) Усиление активности т-клеток car путем совместного введения биспецифического антитела
CY1123046T1 (el) Ζωα εκτος του ανθρωπου που εχουν ανθρωποποιημενους υποδοχεις fc-γ
GB201620536D0 (en) Nucleic acid for coding chimeric antigen receptor protein and t lymphocyte for expression of chimeric antigen receptor protein
EP3833363A4 (en) METHODS AND COMPOSITIONS FOR STIMULATING CHIMERIC ANTIGEN RECEPTOR T-CELLS WITH HAPTEN-TAGGED CELLS
MX2018012868A (es) Composiciones y metodos para generar anticuerpos basado en el uso de loci potenciadores de expresion.
BR112016011003A2 (pt) animal roedor geneticamente modificado, célula tronco embrionária de camundongo, embrião de camundongo, e, métodos para fabricar um animal roedor e para enxertar células humanas em um camundongo
EP3329282A4 (en) QUALITY OF IMMUNOLOGICAL SYNAPSE AS THE PREDICTOR OF THE EFFECTIVENESS OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS
NZ737423A (en) Method for generating antibodies against t cell receptor

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]